ANEB (Anebulo Pharmaceuticals) Short-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Anebulo Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Anebulo Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil.

Anebulo Pharmaceuticals Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Anebulo Pharmaceuticals's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Short-Term Debt & Capital Lease Obligation Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Short-Term Debt & Capital Lease Obligation

0.20

Anebulo Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

Anebulo Pharmaceuticals Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Anebulo Pharmaceuticals Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Executives

22nw Fund, Lp	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Bimal R. Shah	director	C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George	officer: Chief Financial Officer	1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner	officer: Acting Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy	officer: Chief Scientific Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen	director, officer: Chief Executive Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English	director, 10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin	director	PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949
Joseph F. Lawler	director, 10 percent owner	2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp	10 percent owner, other: See Explanation of Response	590 1ST AVE S, UNIT C1, SEATTLE WA 98104